» Articles » PMID: 24968775

Life-long Consequences of Juvenile Exposure to Psychotropic Drugs on Brain and Behavior

Overview
Journal Prog Brain Res
Publisher Elsevier
Specialty Neurology
Date 2014 Jun 28
PMID 24968775
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Psychostimulants such as methylphenidate (MPH) and antidepressants such as fluoxetine (FLX) are widely used in the treatment of various mental disorders or as cognitive enhancers. These medications are often combined, for example, to treat comorbid disorders. There is a considerable body of evidence from animal models indicating that individually these psychotropic medications can have detrimental effects on the brain and behavior, especially when given during sensitive periods of brain development. However, almost no studies investigate possible interactions between these drugs. This is surprising given that their combined neurochemical effects (enhanced dopamine and serotonin neurotransmission) mimic some effects of illicit drugs such as cocaine and amphetamine. Here, we summarize recent studies in juvenile rats on the molecular effects in the mid- and forebrain and associated behavioral changes, after such combination treatments. Our findings indicate that these combined MPH+FLX treatments can produce similar molecular changes as seen after cocaine exposure while inducing behavioral changes indicative of dysregulated mood and motivation, effects that often endure into adulthood.

Citing Articles

Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats.

Hrabak M, Ahmed R, Soriano M, Powell A, Thanos P, Steiner H Mol Neurobiol. 2024; 62(4):4520-4532.

PMID: 39466575 DOI: 10.1007/s12035-024-04569-8.


Vilazodone, a Selective Serotonin Reuptake Inhibitor with Diminished Impact on Methylphenidate-Induced Gene Regulation in the Striatum: Role of 5-HT1A Receptor.

Hrabak M, Moon C, Bolanos-Guzman C, Steiner H Mol Neurobiol. 2023; 61(4):1907-1919.

PMID: 37807008 PMC: 10978284. DOI: 10.1007/s12035-023-03688-y.


High-level psychotropic polypharmacy: a retrospective comparison of children in foster care to their peers on Medicaid.

Davis D, Lohr W, Feygin Y, Creel L, Jawad K, Jones V BMC Psychiatry. 2021; 21(1):303.

PMID: 34112146 PMC: 8194140. DOI: 10.1186/s12888-021-03309-9.


The 5-HT1B serotonin receptor regulates methylphenidate-induced gene expression in the striatum: Differential effects on immediate-early genes.

Alter D, Beverley J, Patel R, Bolanos-Guzman C, Steiner H J Psychopharmacol. 2017; 31(8):1078-1087.

PMID: 28720013 PMC: 5540766. DOI: 10.1177/0269881117715598.


Neurofeedback Therapy for Enhancing Visual Attention: State-of-the-Art and Challenges.

Ordikhani-Seyedlar M, Lebedev M, Sorensen H, Puthusserypady S Front Neurosci. 2016; 10:352.

PMID: 27536212 PMC: 4971093. DOI: 10.3389/fnins.2016.00352.


References
1.
Andersen S . Stimulants and the developing brain. Trends Pharmacol Sci. 2005; 26(5):237-43. DOI: 10.1016/j.tips.2005.03.009. View

2.
Bhatara V, Feil M, Hoagwood K, Vitiello B, Zima B . National trends in concomitant psychotropic medication with stimulants in pediatric visits: practice versus knowledge. J Atten Disord. 2004; 7(4):217-26. DOI: 10.1177/108705470400700404. View

3.
Van Waes V, Carr B, Beverley J, Steiner H . Fluoxetine potentiation of methylphenidate-induced neuropeptide expression in the striatum occurs selectively in direct pathway (striatonigral) neurons. J Neurochem. 2012; 122(5):1054-64. PMC: 3423503. DOI: 10.1111/j.1471-4159.2012.07852.x. View

4.
Covington 3rd H, Kikusui T, Goodhue J, Nikulina E, Hammer Jr R, Miczek K . Brief social defeat stress: long lasting effects on cocaine taking during a binge and zif268 mRNA expression in the amygdala and prefrontal cortex. Neuropsychopharmacology. 2004; 30(2):310-21. DOI: 10.1038/sj.npp.1300587. View

5.
Volkow N, Wang G, Fowler J, Logan J, Franceschi D, Maynard L . Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 2002; 43(3):181-7. DOI: 10.1002/syn.10038. View